Clinical outcomes of indwelling pleural catheter-related pleural infections: An international multicenter study

Chest

Volumn 144, Issue 5, 2013, Pages 1597-1602

  Fysh, Edward T H ^a,b,c   Tremblay, Alain ^d   Feller Kopman, David ^e   Mishra, Eleanor K ^f   Slade, Mark ^g   Garske, Luke ^h   Clive, Amelia O ⁱ   Lamb, Carla ^j   Boshuizen, Rogier ^k   Ng, Benjamin J ^l   Rosenstengel, Andrew W ^a   Yarmus, Lonny ^e   Rahman, Najib M ^f   Maskell, Nick A ⁱ   Gary Lee, Y C ^a,b,c,m  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF CALGARY   (Canada)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g PAPWORTH HOSPITAL   (United Kingdom)

^h PRINCESS ALEXANDRA HOSPITAL   (Australia)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

^j LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^k NETHERLANDS CANCER INSTITUTE   (Netherlands)

^l NEPEAN HOSPITAL   (Australia)

^m PATHWEST LABORATORY MEDICINE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DEOXYRIBONUCLEASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; CANCER GROWTH; CATHETER INFECTION; CAUSE OF DEATH; EUROPE; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; INDWELLING CATHETER; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NORTH AMERICA; PATHOGENESIS; PLEURAL CATHETER; PLEURISY; PLEURODESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYMPTOM;

EID: 84887496608     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-3103     Document Type: Article

References (24)

1. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383-2389.
2. Fysh E T H, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest. 2012;142(2):394-400.
3. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129(2):362-368.
4. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86(10):1992-1999.
5. Suzuki K, Servais EL, Rizk NP, et al. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. J Thorac Oncol. 2011;6(4):762-767.
6. Janes SM, Rahman NM, Davies R J O, Lee Y C G. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest. 2007;131(4):1232-1234.
7. Fysh ET, Wrightson JM, Lee Y C G, Rahman NM. Fractured indwelling pleural catheters. Chest. 2012;141(4):1090-1094.
8. Wrightson JM, Fysh E, Maskell NA, Lee Y C G. Risk reduction in pleural procedures: sonography, simulation and supervision. Curr Opin Pulm Med. 2010;16(4):340-350.
9. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70-76.
10. Tremblay A, Stather DR, Maceachern P. How should we manage empyema complicating tunneled pleural catheter placement? J Bronchology Interv Pulmonol. 2010;17(2):106-108.
11. Mahmood K, Bower C. Treatment of infection associated with tunneled pleural catheters. J Bronchology Interv Pulmonol 2010;17(1):69-72.
12. Antevil JL, Putnam JB Jr. Talc pleurodesis for malignant effusions is preferred over the pleurx catheter (pro position). Ann Surg Oncol. 2007;14(10):2698-2699.
13. Maskell NA, Davies C W H, Nunn AJ, et al; First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U. K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352(9):865-874.
14. Morel A, Mishra E, Medley L, et al. Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion. Thorax. 2011;66(5):448-449.
15. Tobin CL, Lee Y C G. Pleural infection: what we need to know but don't. Curr Opin Pulm Med. 2012;18(4):321-325.
16. Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest. 2004;126(5):1529-1539.
17. Rahman NM, Davies HE, Salzberg M, et al. Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. Lancet Oncol 2008;9(10):946-952.
18. Lee Y C G, Fysh E T H. Indwelling pleural catheter: changing the paradigm of malignant effusion management. J Thorac Oncol. 2011;6(4):655-657.
19. Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009;15(4):380-387.
20. Khaleeq G, Musani AI. Emerging paradigms in the management of malignant pleural effusions. Respir Med. 2008;102(7):939-948.
21. Davies HE, Steer HJ, Fysh ET, Lee Y C G. Diagnosis and management of malignant pleural effusion. Minerva Pneumologica. 2010;49(2):237-252.
22. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526.
23. Lin Y-C, Chen H-J, Liu Y-H, Shih CM, Hsu WH, Tu CY. A 30-month experience of thoracic empyema in a tertiary hospital: emphasis on differing bacteriology and outcome between the medical intensive care unit (MICU) and medical ward. South Med J. 2008;101(5):484-489.
24. Kishi K, Homma S, Sakamoto S, et al. Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions. Eur Respir J. 2004;24(2):263-266.